No matter how cynical the overall market is, Biogen Inc (BIIB) performance over the last week is recorded -4.18%

Biogen Inc (NASDAQ: BIIB) on Tuesday, plunged -3.35% from the previous trading day, before settling in for the closing price of $214.83. Within the past 52 weeks, BIIB’s price has moved between $211.01 and $319.76.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Healthcare Sector giant saw their annual sales slid by -4.53% over the last five years. The company achieved an average annual earnings per share of 5.49%. With a float of $144.19 million, this company’s outstanding shares have now reached $144.90 million.

The firm has a total of 7570 workers. Let’s measure their productivity.

Biogen Inc (BIIB) Breakdown of a Key Holders of the stock

Observing investor behavior towards Drug Manufacturers – General industry stocks is more important than anything else. The insider ownership of Biogen Inc is 0.80%, while institutional ownership is 90.17%. The most recent insider transaction that took place on Feb 22 ’24, was worth 57,962. In this transaction Head of Development of this company sold 262 shares at a rate of $221.23, taking the stock ownership to the 4,886 shares. Before that another transaction happened on Feb 16 ’24, when Company’s Head of Development sold 108 for $221.49, making the entire transaction worth $23,921. This insider now owns 5,148 shares in total.

Biogen Inc (BIIB) Recent Fiscal highlights

As on 12/30/2023, Multinational firm has announced its last quarter scores, in which it reported $3.3 earnings per share (EPS) for the period topping the consensus outlook (set at $3.18) by $0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.94 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 5.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.80% during the next five years compared to -18.05% drop over the previous five years of trading.

Biogen Inc (NASDAQ: BIIB) Trading Performance Indicators

Biogen Inc (BIIB) is currently performing well based on its current performance indicators. A quick ratio of 1.26 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.21.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 7.98, a number that is poised to hit 3.47 in the next quarter and is forecasted to reach 17.67 in one year’s time.

Technical Analysis of Biogen Inc (BIIB)

Analysing the last 5-days average volume posted by the [Biogen Inc, BIIB], we can find that recorded value of 1.41 million was better than the volume posted last year of 1.18 million. As of the previous 9 days, the stock’s Stochastic %D was 26.34%. Additionally, its Average True Range was 4.84.

During the past 100 days, Biogen Inc’s (BIIB) raw stochastic average was set at 0.10%, which indicates a significant decrease from 0.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 22.09% in the past 14 days, which was lower than the 26.97% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $228.15, while its 200-day Moving Average is $251.05. Now, the first resistance to watch is $211.53. This is followed by the second major resistance level at $215.41. The third major resistance level sits at $217.39. If the price goes on to break the first support level at $205.67, it is likely to go to the next support level at $203.69. Now, if the price goes above the second support level, the third support stands at $199.81.

Biogen Inc (NASDAQ: BIIB) Key Stats

Market capitalization of the company is 30.18 billion based on 145,361K outstanding shares. Right now, sales total 9,836 M and income totals 1,161 M. The company made 2,386 M in profit during its latest quarter, and 249,700 K in sales during its previous quarter.